In 2023, 4,514 clinical cases were reported across 36 states and Washington, D.C. Clinical cases refer to those in which infection is present, whereas screening cases refer to those where fungus is detected and has colonized, but has not led to infection.
This is a significant jump from 2022, when 2,928 clinical cases were reported. C. auris is considered an urgent public health threat due to its resistance to multiple antifungal treatments and ability to spread quickly in healthcare settings, particularly among immunocompromised people.
Below is a list of the number of clinical cases reported in the U.S. in 2023, per the CDC:
California: 642
Nevada: 599
Florida: 568
Texas: 492
Illinois: 477
New York: 413
Georgia: 192
Ohio: 161
Arizona: 124
Michigan: 114
Indiana: 113
Tennessee: 99
Maryland: 97
Virginia: 81
New Jersey: 75
Pennsylvania: 39
Mississippi: 35
Louisiana: 28
Delaware: 25
District of Columbia: 23
Kentucky: 19
North Carolina: 18
Alabama: 13
Wisconsin: 11
Arkansas: 9
Oklahoma: 8
South Carolina: 7
Massachusetts: 6
Iowa: 5
Minnesota: 5
Connecticut: 4
West Virginia: 4
Colorado: 2
Missouri: 2
Oregon: 2
Nebraska: 1
Utah: 1
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
